GLP-1 TRZP
Research Compound GLP-1 TRZP (CAS 2023788-19-2)
A dual GLP-1/GIP receptor co-agonist studied for incretin pathway synergy, insulin secretion modulation, and body weight regulation in preclinical metabolic models.
ESI-MS identity confirmed · Batch-specific COA included
Compound Specifications
2023788-19-2
4813.48 g/mol
Lyophilized Powder
-20°C
Available Sizes
For laboratory research use only. Not for human or animal consumption. Must be 21+. This product is not intended to diagnose, treat, cure, or prevent any disease. Nothing on this site constitutes medical advice.
HPLC Verified
Reverse-phase HPLC purity analysis on every production batch. Raw chromatogram data included on COA.
ESI-MS Confirmed
Electrospray ionization mass spectrometry confirms molecular weight and sequence identity for every lot.
Batch-Specific COA
Each order ships with a certificate of analysis tied to its unique lot number — not a generic document.
More in Metabolic
Metabolic
GLP-1-RTA
98.5% purity
A triple incretin receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Studied for its role in multi-receptor metabolic signaling, energy homeostasis, and adipose tissue regulation in preclinical models.